Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.

Literature DB >> 24795814

Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.

Socrates E Papapoulos¹.

Abstract

Entities: Disease Gene

Year: 2014 PMID： 24795814 PMCID： PMC4007168 DOI： 10.1038/bonekey.2014.18

Source DB: PubMed Journal: Bonekey Rep ISSN： 2047-6396

× No keyword cloud information.

9 in total

Review 1. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.

Authors: Hua Zhu Ke; William G Richards; Xiaodong Li; Michael S Ominsky
Journal: Endocr Rev Date: 2012-06-20 Impact factor: 19.871

2. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women.

Authors: Juliet McColm; Leijun Hu; Theresa Womack; Cheng Cai Tang; Alan Y Chiang
Journal: J Bone Miner Res Date: 2014-04 Impact factor: 6.741

3. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.

Authors: Desmond Padhi; Graham Jang; Brian Stouch; Liang Fang; Edward Posvar
Journal: J Bone Miner Res Date: 2011-01 Impact factor: 6.741

4. Romosozumab in postmenopausal women with low bone mineral density.

Authors: Michael R McClung; Andreas Grauer; Steven Boonen; Michael A Bolognese; Jacques P Brown; Adolfo Diez-Perez; Bente L Langdahl; Jean-Yves Reginster; Jose R Zanchetta; Scott M Wasserman; Leonid Katz; Judy Maddox; Yu-Ching Yang; Cesar Libanati; Henry G Bone
Journal: N Engl J Med Date: 2014-01-01 Impact factor: 91.245

1 in total

1. Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro.

Authors: Cyril Thouverey; Joseph Caverzasio
Journal: Bonekey Rep Date: 2015-11-04

1 in total

Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.

Review 1. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.

2. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women.

3. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.

4. Romosozumab in postmenopausal women with low bone mineral density.

5. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.

Review 6. WNT signaling in bone homeostasis and disease: from human mutations to treatments.

7. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers.

Review 8. Sclerostin: current knowledge and future perspectives.

9. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.

1. Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro.